In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 6, 2000, Pages 899-901

  Christenson, John C ^a   Korgenski, E Kent ^a   Daly, Judy A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; IMIPENEM; MEROPENEM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CYSTIC FIBROSIS; HUMAN; LUNG INFECTION; PSEUDOMONAS AERUGINOSA;

EID: 0034091464     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.6.899     Document Type: Article

References (12)

1. Gilligan, P. H. (1991). Microbiology of airway disease in patients with cystic fibrosis. Clinical Microbiology Reviews 4, 35-51.
2. Webb, A. K. (1995). The treatment of pulmonary infection in cystic fibrosis. Scandinavian Journal of Infectious Diseases 96, Suppl., 24-7.
3. Arrieta, A. (1997). Use of meropenem in the treatment of serious infections in children: review of the current literature. Clinical Infectious Diseases 24, Suppl. 2, S207-12.
4. Ballestero, S., Fernandez-Rodriquez, A., Villaverde, R., Escobar, H., Perez-Diaz, J. C. & Baquero, F. (1996). Carbapenem resistance in Pseudomonas aeruginosa from cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 38, 39-45.
5. Byrne, S., Maddison, J., Connor, P., Doughty, I., Dodd, M., Jenney, M. et al. (1995). Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 36, Suppl. A, 135-43.
6. Huls, C. E., Prince, R. A., Seilheimer, D. K. & Bosso, J. A. (1993). Pharmokinetics of cefepime in cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 37, 1414-6.
7. Barradell, L. B. & Bryson, H. M. (1994). Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 47, 471-505.
8. National Committee for Clinical Laboratory Standards. (1997). Performance Standards for Antimicrobial Disk Susceptibility Tests - Sixth Edition: Approved Standard M2-A6. NCCLS, Villanova, PA.
9. National Committee for Clinical Laboratory Standards. (1997). Performance Standards for Antimicrobial Susceptibility Tests: Approved Standard M100-S7. NCCLS, Villanova, PA.
10. Zeneca Pharmaceuticals. (1996). Susceptibility Test Criteria. Zeneca Pharmaceuticals. Wilmington, DE.
11. Bauernfeind, A., Jungwirth, R. & Schweighart, S. (1989). In-vitro activity of meropenem, imipenem, the penem HRE 664 and ceftazidime against clinical isolates from West Germany. Journal of Antimicrobial Chemotherapy 24, Suppl. A, 73-84.
12. Ballestero, S., Fernandez-Rodriguez, A., Villaverde, R., Escobar, H., Perez-Diaz, J. C. & Baquero, F. (1996). Carbapenem resistance in Pseudomonas aeruginosa from cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 38, 39-45.